Active Studies

Study VX16-661-114 (Study 114) is a Phase 3b, randomized, double-blind, placebo-controlled,
parallel group, multicenter study in subjects aged 12 years and older with CF who are
homozygous for the F508del mutation on the CFTR gene and who discontinued treatment with
Orkambi due to respiratory symptoms considered related to treatment. This study is designed
to evaluate the safety and efficacy of TEZ/IVA.

In support of the US marketing application for 5-ALA, this single arm trial is being
conducted to establish the efficacy and safety of Gliolan (5-ALA) in patients with newly
diagnosed or recurrent malignant gliomas. The hypothesis of the study is Gliolan (5-ALA), as
an adjunct to tumor resection, is safe and that real-time tissue fluorescence correlates with
malignant histopathology. The primary objective in this single arm study is to define the
positive predictive value (PPV) of Gliolan-induced PPIX fluorescence for malignant tumor at
the time of initial resection and first use of FGS by taking a biopsy of tissue presenting
with red fluorescence when observed during the course of resection of new or recurrent
malignant gliomas. The functionality and performance reliability of the blue light excitation
microscope platforms will be assessed.

Please ignore this page

Deficits in both the peripheral and central nervous systems are important complications found in people with Type 2 diabetes (T2D). Conditions such diabetic peripheral neuropathy (DPN) and slowing of the neural signals in the brain have been described in subjects with T2D, which are consistent with motor control and cognitive impairments observed in this population. A good cognitive and motor control is essential for manual function and dexterity such as drinking from a glass, buttoning a shirt, and, in case of people with diabetes, checking blood glucose levels or giving self-injections.

The main objective of this research project is to investigate the cognitive effort, measured by pupil dilation, during dual tasking and its accurate prediction of falls in Parkinson's disease 

Compensation will be available for your participation in the study.